Neurocrine Biosciences
NBIX
#1573
Rank
โ‚ฌ11.38 B
Marketcap
113,44ย โ‚ฌ
Share price
2.56%
Change (1 day)
5.33%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): 4,11ย โ‚ฌ

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is 4,17ย โ‚ฌ. an increase over its 2024 EPS that were of 2,92ย โ‚ฌ.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
20254,03ย โ‚ฌ37.87%
20242,92ย โ‚ฌ33.07%
20232,20ย โ‚ฌ57.76%
20221,39ย โ‚ฌ69.47%
20210,82ย โ‚ฌ-78.21%
20203,77ย โ‚ฌ990%
20190,35ย โ‚ฌ81.82%
20180,19ย โ‚ฌ-113.5%
2017-1,41ย โ‚ฌ0.62%
2016-1,40ย โ‚ฌ57.28%
2015-0,89ย โ‚ฌ25.61%
2014-0,71ย โ‚ฌ18.84%
2013-0,60ย โ‚ฌ-1085.71%
20120,06056ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
1,18ย โ‚ฌ-71.78%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
2,07ย โ‚ฌ-50.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
19,92ย โ‚ฌ 377.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
0,75ย โ‚ฌ-81.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-1,76ย โ‚ฌ-142.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
1,48ย โ‚ฌ-64.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-25,87ย โ‚ฌ-720.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
1,52ย โ‚ฌ-63.56%๐Ÿ‡ฌ๐Ÿ‡ง UK